Global Antimalarial Drugs Market Size, Share, Forecast Report, 2020-2027

The global antimalarial drugs market accounted for $711,360 thousand in 2018 and is expected to reach $1,019,396 thousand by 2026, registering a CAGR of 4.6% from 2019 to 2026.

Malaria is an infectious disease, which spreads through a bite of infected female Anopheles mosquito, transferring parasites into the human body. Furthermore, these parasites lodge into liver cells where they multiply and grow. They then move to red blood cells to reach a stage called merozoites. These merozoites grow inside the red cells and destroy them which further cause symptoms such as fever, tiredness, vomiting, and headache. In addition, the drugs that are used to treat and prevent malarial infection are called as antimalarial. There are different type of drugs, such as quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others, available in the market for the treatment of malarial infection.
The major factor that drives the growth of the antimalarial drugs market include rise in prevalence of malaria in developing countries. Furthermore, rise in awareness initiatives by governments and surge in research for new antimalarial drugs are some of the factors that boost the growth of the market. However, lack of awareness about healthcare in developing countries is a major factor that restrains the growth of the antimalarial drugs market. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities for the market expansion during the forecast period.

Antimalarial Drugs Market Segmentation

The antimalarial drugs market size is studied on the basis of drug class, distribution channel, and region to provide a detailed assessment of the market. On the basis of drug class, it is segmented into quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others. By distribution channel, it is divided into hospital pharmacy, retail pharmacy, and e-commerce & other distribution channel. Region wise, it is analyzed across North America (the U.S. and Canada), Europe (Germany, the UK, and rest of Europe), Asia-Pacific (China, India, and rest of Asia-Pacific), and LAMEA (Africa and rest of LAMEA).

Segment Review

According to drug class, the others segment occupied the major share of the antimalarial drugs market. Furthermore, the segment is also expected to exhibit the fastest growth rate during the forecast period, owing to factor that malaria parasites have successfully developed resistance against most of the drugs already available in the market.
By distribution channel, the hospital pharmacy segment acquired the major share due to rise in number of hospitals worldwide. Furthermore, antimalarial drugs are prescription-based medications, which are mostly prescribed by the specialized healthcare professionals available in hospitals; thereby, propelling the growth of this segment. Conversely, the e-commerce segment is expected to exhibit the fastest growth rate during the forecast period, owing to surge in the usage of internet across the globe.

By region, LAMEA accounted for the major antimalarial drugs market share in 2018 and is expected to continue this trend, owing to rapid surge in prevalence of malaria in the region. Moreover, the widespread of the malaria vector, Anopheles gambiae, in the region, which is difficult to control is another major factor that leads to surge in cases of malaria. Furthermore, most of the malarial infections in this region are caused by the most lethal type of malarial parasite called Plasmodium falciparum. Therefore, there is a need for early diagnosis of malarial infection in this region, which further boosts the growth of the market. In addition, malaria infection is endemic to some parts of Africa, which fuels the growth of the market in the region. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period due to increase in awareness regarding the use of antimalarial drugs for early diagnosis of the infection for better treatment. The constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia. As the constant development leads to surge in awareness related to the use of antimalarial drugs.
The global antimalarial drugs market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Alvizia Healthcare Pvt. Ltd., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Merck & Co., Inc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories), and Zydus Cadila.

Key Benefits for Stakeholders:

• This report entails a detailed quantitative analysis along with the current global antimalarial drugs market trends from 2018 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The antimalarial drugs market forecast is studied from 2019 to 2026. 
• The market size and estimations are based on a comprehensive analysis of key developments in the industry. 
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the antimalarial drugs market.

Key Market Segments:

By Drug Class

• Quinine
• Chloroquine
• Proguanil
• Mefloquine
• Pyrimethamine
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• E-Commerce & Other Distribution Channel

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany 
  • UK 
  • Rest of Europe
• Asia-Pacific
  • China 
  • India 
  • Rest of Asia-Pacific
• LAMEA
  • Africa
  • Rest of LAMEA